Literature DB >> 24397841

Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan.

.   

Abstract

Entities:  

Year:  2014        PMID： 24397841     DOI： 10.1111/hepr.12270

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  30 in total

1.  Anti-mitochondrial autoantibodies-milestone or byway to primary biliary cholangitis?

Authors:  Atsushi Tanaka
Journal:  Ann Transl Med       Date:  2017-02

2.  Increased hepatic ABCA1 transporter is associated with hypercholesterolemia in a cholestatic rat model and primary biliary cholangitis patients.

Authors:  Yasuaki Takeyama; Yuko Uehara; Akira Anan; Daisuke Morihara; Keiji Yokoyama; Kazuhide Takata; Takashi Tanaka; Makoto Irie; Kaoru Iwata; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka
Journal:  Med Mol Morphol       Date:  2017-06-28       Impact factor: 2.309

3.  The therapeutic effect of UDCA is a factor in determining the prognosis of primary biliary cirrhosis.

Authors:  Mikio Zeniya; Takashi Wada
Journal:  J Gastroenterol       Date:  2014-06-05       Impact factor: 7.527

4.  A case of primary biliary cholangitis overlapping with type 2 autoimmune hepatitis.

Authors:  Nozomi Amano; Sho Sato; Ayato Murata; Hironori Tsuzura; Ko Tomishima; Shunsuke Sato; Kohei Matsumoto; Yuji Shimada; Katsuyori Iijima; Kenichi Harada; Takuya Genda
Journal:  Clin J Gastroenterol       Date:  2019-07-08

5.  Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Authors:  Maren H Harms; Willem J Lammers; Douglas Thorburn; Christophe Corpechot; Pietro Invernizzi; Harry L A Janssen; Pier M Battezzati; Frederik Nevens; Keith D Lindor; Annarosa Floreani; Cyriel Y Ponsioen; Marlyn J Mayo; George N Dalekos; Tony Bruns; Albert Parés; Andrew L Mason; Xavier Verhelst; Kris V Kowdley; Jorn C Goet; Gideon M Hirschfield; Bettina E Hansen; Henk R van Buuren
Journal:  Am J Gastroenterol       Date:  2017-12-12       Impact factor: 10.864

Review 6.  Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.

Authors:  Atsushi Tanaka; Xiong Ma; Osamu Yokosuka; Martin Weltman; Hong You; Deepak N Amarapurkar; Yoon Jun Kim; Zaigham Abbas; Diana A Payawal; Ming-Ling Chang; Cumali Efe; Ersan Ozaslan; Masanori Abe; Robert Mitchell-Thain; Mikio Zeniya; Kwang Hyub Han; John M Vierling; Hajime Takikawa
Journal:  Hepatol Int       Date:  2016-09-20       Impact factor: 6.047

7.  Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.

Authors:  Atsushi Tanaka; Junko Hirohara; Yasuni Nakanuma; Hirohito Tsubouchi; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2014-09-20       Impact factor: 7.527

8.  Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.

Authors:  Minami Yagi; Atsushi Tanaka; Tadashi Namisaki; Atsushi Takahashi; Masanori Abe; Akira Honda; Yasushi Matsuzaki; Hiromasa Ohira; Hitoshi Yoshiji; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-04-16       Impact factor: 7.527

9.  Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases.

Authors:  Alanna M K Dubrovsky; Christopher L Bowlus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-01

Review 10.  Genetics and epigenetics in the pathogenesis of primary biliary cholangitis.

Authors:  Satoru Joshita; Takeji Umemura; Eiji Tanaka; Masao Ota
Journal:  Clin J Gastroenterol       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.